Literature DB >> 18237748

Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample.

K A Ganasen1, D Fincham, J Smit, S Seedat, D Stein.   

Abstract

BACKGROUND: The Mini Mental State Examination (MMSE) has been traditionally used to screen for cognitive impairment in a variety of dementing illnesses, including HIV associated dementia. More recently, the HIV Dementia Scale (HDS) was developed as a bedside evaluation test to differentiate patients with HIV-associated frank dementia from those who are cognitively normal.
OBJECTIVE: This study assessed the sensitivity and specificity of the HDS (using the MMSE as the gold standard) in a sample of 474 patients attending anti-retroviral (ARV) services in the Cape Town metropole of South Africa. None of these patients had a pre-existing clinical diagnosis of dementia based on a review of the medical records.
RESULTS: The HDS and MMSE were significantly correlated and showed significant agreement. Nonetheless, the HDS identified more participants demonstrating cognitive impairment than the MMSE. An ROC curve analysis revealed that an HDS cut-off of < or =10 yielded a sensitivity of 80%, specificity of 80%, and discriminated between the presence and absence of cognitive impairment 90% of the time.
CONCLUSION: Our findings suggest that the HDS may be a more sensitive screening instrument for HIV associated dementia in patients attending ARV services.

Entities:  

Mesh:

Year:  2008        PMID: 18237748     DOI: 10.1016/j.jns.2007.12.027

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  20 in total

1.  Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.

Authors:  Norma Kabuba; J Anitha Menon; Donald R Franklin; Robert K Heaton; Knut A Hestad
Journal:  AIDS Behav       Date:  2017-06

2.  Diagnostic Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Impairment and Disorder in South Africa.

Authors:  Karl Goodkin; David J Hardy; Dinesh Singh; Enrique Lopez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2014       Impact factor: 2.198

Review 3.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

Review 4.  Screening for cognitive impairment in human immunodeficiency virus.

Authors:  Victor Valcour; Robert Paul; Stephanie Chiao; Lauren A Wendelken; Bruce Miller
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

5.  HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia.

Authors:  Adelina Holguin; Mwanza Banda; Elizabeth J Willen; Costantine Malama; Kaseya O Chiyenu; Victor C Mudenda; Charles Wood
Journal:  AIDS Behav       Date:  2011-11

6.  Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting.

Authors:  Reuben N Robbins; Robert H Remien; Claude A Mellins; John A Joska; Dan J Stein
Journal:  AIDS Patient Care STDS       Date:  2011-09-15       Impact factor: 5.078

7.  Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools.

Authors:  Victor G Valcour
Journal:  Top Antivir Med       Date:  2011-12

Review 8.  Neurology and the Global HIV Epidemic.

Authors:  Ana-Claire Meyer
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

9.  Exploring the utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa.

Authors:  Reuben N Robbins; John A Joska; Kevin G F Thomas; Dan J Stein; Teboho Linda; Claude A Mellins; Robert H Remien
Journal:  Clin Neuropsychol       Date:  2013-01-21       Impact factor: 3.535

10.  The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years.

Authors:  Benedetta Milanini; Lauren A Wendelken; Pardis Esmaeili-Firidouni; Maggie Chartier; Pierre-Cedric Crouch; Victor Valcour
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.